Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

Journal of Diabetes Investigation

Volumn 6, Issue 6, 2015, Pages 692-698

  Chen, Yuhong ^a   Ning, Guang ^a   Wang, Changjiang ^b   Gong, Yan ^c   Patel, Sanjay ^d   Zhang, Candice ^e   Izumoto, Toshiyasu ^f   Woerle, Hans Juergen ^c   Wang, Weiqing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM LTD   (United Kingdom)

^e State Key Laboratory of Dairy Biotechnology   (China)

^f NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Asians; Linagliptin; Monotherapy

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ASIAN; CHINESE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PANCREAS CANCER; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; THORAX DISEASE; URTICARIA;

EID: 84945457381     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12346     Document Type: Article

References (22)

1. International Diabetes Federation. IDF Diabetes Atlas. 2011. Available at: www.idf.org/diabetesatlas/ (accessed April 18 2014).
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
3. Ramachandran A, Snehalatha C, Vijay V. Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004; 65: 189-195.
4. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013; 1281: 64-91.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
6. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012; 51: 411-427.
7. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012; 74: 75-85.
8. Boehringer Ingelheim Ltd. Trajenta Summary of Product Characteristics. 2013. Available at: http://www.medicines.org.uk/emc/medicine/25000/spc (accessed March 20 2013).
9. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-267.
10. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-661.
11. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
12. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
13. Zeng Z, Choi DS, Mohan V, et al. Linagliptin is efficacious and well tolerated in Asian patients with inadequately controlled type 2 diabetes. Diabetes 2012; 61(Suppl 1): A300.
14. Zeng Z, Yang JK, Tong N, et al. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin 2013; 29: 921-929.
15. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
16. White W. Results from EXAMINE. Oral presentation at EASD 2013. Available at: http://www.easdvirtualmeeting.org/resources/7109 [accessed 16 December 2014].
17. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289-301.
18. Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012; 28: 268-275.
19. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009; 83: 106-116.
20. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. Available at: http://www.idf.org/global-guideline-type-2-diabetes-2012 (accessed October 2 2013).
21. Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 833-843.
22. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012; 14: 348-357.